Success Stories
Neurovascular Inflammatory Group Continue Ground-Breaking Research
The work of the group encompasses fundamental molecular biology and cell studies, studies on animal models, clinical research and medicinal chemistry in the development and screening of novel compounds.
NIG continue to make ground-breaking advances in this area. A paper entitled 'Proteinase-activated receptor-2 (PAR2) mediates the pro-inflammatory effects of synovial mast cells', based on the doctoral studies of Helen Palmer, has been accepted for publication in Arthritis & Rheumatism (2007), the 3 rd paper published this year in the premier journal for Rheumatology research.
The group have recently identified and validated two new clinical targets for arthritic diseases and which are key to understanding and ultimately controlling the disorders. The group has a high international standing in the academic world and in the pharmaceutical world. A Scottish Enterprise Life Science Business Advisor who recently visited the research facilities has described the Groups work as 'world class research in identifying, characterising and validating two new receptors'.